Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole

Journal of Clinical Gastroenterology

Volumn 40, Issue 6, 2006, Pages 515-520

  Giannini, Edoardo G ^a,b   Bilardi, Claudio ^a   Dulbecco, Pietro ^a   Mamone, Mario ^a   Santi, Maria L ^b   Testa, Roberto ^a   Mansi, Carlo ^a   Savarino, Vincenzo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Italian Association of the Sovereign Hospitaller Order of St John of Jerusalem Rhodes and Malta   (Malta)

Author keywords

Eradication therapy; Helicobacter pylori; Levofloxacin; Rabeprazole; Tinidazole

Indexed keywords

CARBON 13; LEVOFLOXACIN; RABEPRAZOLE; TINIDAZOLE; UREA; VALSARTAN;

ADULT; AGED; ARTICLE; BLOATING; CLINICAL PRACTICE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; ENDOSCOPY; EPIGASTRIC PAIN; FEMALE; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LITERATURE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; STATISTICAL SIGNIFICANCE; TASTE DISORDER; TENDINITIS; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ANTITRICHOMONAL AGENTS; BENZIMIDAZOLES; BREATH TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OFLOXACIN; OMEPRAZOLE; PILOT PROJECTS; TINIDAZOLE; TREATMENT OUTCOME;

EID: 33748263770     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200607000-00010     Document Type: Article

References (45)

1. Williams MP, Pounder RE. Helicobacter pylori: from the benign to the malignant. Am J Gastroenterol. 1999;94(Suppl):11S-16S.
2. Hunt RH. Peptic ulcer disease: defining the treatment strategies in the era of Helicobacter pylori. Am J Gastroenterol. 1997;92(Suppl):36S-40S.
3. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-180.
4. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2330-2338.
5. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 1998;13:1-12.
6. Lee JM, Breslin NP, Hyde DK, et al. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther. 1999;13:489-496.
7. Della Monica P, Lavagna A, Masoero G, et al. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther. 2002;16:1269-1275.
8. Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol. 1998;93:1432-1435.
9. McLoughlin R, Racz I, Buckley M, et al. Therapy of Helicobacter pylori. Helicobacter. 2004;9(Suppl 1):42-48.
10. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:1339-1343.
11. Nista EC, Candelli F, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther. 2003;18:627-633.
12. Zullo A, Hassan C, De Francesco V, et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Digest Liver Dis. 2003;35:232-236.
13. Cammarota G, Cianci R, Cannizzaro O, et al. High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication. J Clin Gastroenterol. 2004;38:110-114.
14. Gambaro C, Bilardi C, Dulbecco P, et al. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. Digest Liver Dis. 2003;35:763-767.
15. Gené E, Calvet X, Azagra R, et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment Pharmacol Ther. 2003;18:543-544.
16. Gené E, Calvet X, Azagra R, et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther. 2003;17:1137-1143.
17. Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol. 2004;2:997-1002.
18. Logan RPH, Dill S, Bauer FE, et al. The European 13C-urea breath test for the detection of Helicobacter pylori. Eur J Gastroenterol Hepatol. 1991;3:915-921.
19. Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20:99-107.
20. O'Connor HJ, McLoughlin R, Kelly S, et al. Lansoprazole triple therapy for Helicobacter pylori - is 5 days enough? Aliment Pharmacol Ther. 1998;12:273-276.
21. Trevisani L, Sartori S, Caselli M, et al. A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. Am J Gastroenterol. 1998;93:390-393.
22. Calvet X, Garcia N, Campo R, et al. Two-day quadruple therapy for cure of Helicobacter pylori infection: a comparative randomised trial. Am J Gastroenterol. 1998;93:932-934.
23. Hurenkamp GJB, Van der Ende A, Grundmeijer HGLM, et al. Equally high efficacy of 4, 7, 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. Aliment Pharmacol Ther. 2000;14:1065-1070.
24. Isomoto H, Furusu H, Morikawa T, et al. 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000;14:1619-1623.
25. Wong BCY, Wong WM, Yee YK, et al. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2001;15:1959-1965.
26. Tutuian R, Katz PO, Castell DO. A PPI is a PPI is a PPI; lessons from prolonged intragastric pH monitoring. [Abstract] Gastroenterology. 2000;118(Suppl 2):A17.
27. Altintas E, Sezgin O, Ulu O, et al. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol. 2004;10:1656-1658.
28. Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole. Aliment Pharmacol Ther. 2004;20(Suppl 6):11-19.
29. Giannini E, Romagnoli P, Fasoli A, et al. Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens. Am J Gastroenterol. 2000;95:2762-2767.
30. 13C-aminopyrine breath test. Dig Dis Sci. 2005;50:1207-1213.
31. Giannini EG, Savarino V, Testa R. Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastrooesophageal reflux disease. Dig Dis Sci. In press.
32. Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: and evidence-based approach. Eur J Gastroenterol Hepatol. 2001;13:611-616.
33. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63:2739-2754.
34. Branca G, Spanu T, Cammarota G, et al. High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. Int J Antimicrob Agents. 2004;24:433-438.
35. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374-1384.
36. Manes G, Balzano A. Tinidazole: from protozoa to Helicobacter pylori-the past, present and future of a nitroimidazole with peculiarities. Expert Rev Anti Infect Ther. 2004;2:695-705.
37. Luth S, Teyssen S, Kolbel C, et al. 4-day triple therapy with rabeprazole, amoxicillin, and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease-a pilot study. Z Gastroenterol. 2001;39:279-281.
38. Wang HH, Chou JW, Liao KF, et al. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. World J Gastroenterol. 2005;11:1680-1684.
39. Al-Eidan FA, McElnay JC, Scott MG, et al. Management of Helicobacter pylori eradication - the influence of structured counselling and follow-up. Br J Clin Pharmacol. 2002;53:163-171.
40. Romano M, Marmo R, Cuomo A, et al. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastoenterol Hepatol. 2003;1:273-278.
41. Qasim A, Sebastian S, Buckely M, et al. Pretreatment antimicrobial susceptibility testing is not cost saving in the standard eradication of Helicobacter pylori. Clin Gastroenterol Hepatol. 2004;2:85.
42. Neri M, Milano A, Laterza F, et al. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment Pharmacol Ther. 2003;18:821-827.
43. Coelho LG, Leon-Barua R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol. 2000;95:2688-2691.
44. Gisbert JP, Dominguez-Munoz A, Dominguez-Martin A, et al. Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment. Am J Gastroenterol. 2005;100:1935-1940.
45. Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variable influencing it. A critical review. Am J Gastroenterol. 2005;100:2083-2099.